CST, 84534S, Cleaved SARS-CoV-2 Spike Protein (Ser686) Antibody

Polyclonal Antibody for studying Spike Protein (Ser686, N-term) cleaved SARS-CoV-2. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, Cleaved SARS-CoV-2 Spike Protein (Ser686) Antibody (CST #84534) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity Cleaved SARS-CoV-2 Spike Protein (Ser686) Antibody recognizes SARS-CoV-2 spike protein only when cleaved at the S1/S2 cleavage site to produce the S2 subunit. Based on sequence analyses, this antibody is not predicted to cross-react with coronavirus spike proteins of SARS or MERS. Species Reactivity: Virus Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to N-terminal residues surrounding Ser686 of SARS-CoV-2 spike protein at the S1/S2 cleavage site. Antibodies are purified by peptide affinity chromatography. Background The cause of the COVID-19 pandemic is a novel and highly pathogenic coronavirus, termed SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). SARS-CoV-2 is a member of the Coronaviridae family of viruses (1). The genome of SARS-CoV-2 is similar to other coronaviruses, and is comprised of four key structural proteins: S, the spike protein, E, the envelope protein, M, the membrane protein, and N, the nucleocapsid protein (2). Coronavirus spike proteins are class I fusion proteins and harbor an ectodomain, a transmembrane domain, and an intracellular tail (3,4). The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases at S1/S2 and S2' sites. S1 and S2 subunits remain associated after cleavage and assemble into crown-like homotrimers (2,4). In humans, both SARS-CoV and SARS-CoV-2 spike proteins utilize the angiotensin-converting enzyme 2 (ACE2) protein as a receptor for cellular entry (5-7). Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors (8,9). Alternate Names 2019-nCoV surface glycoprotein; Peplomer protein; S glycoprotein; SARS-CoV-2 spike protein; spike glycoprotein; SPIKE_SARS2; surface glycoprotein Specification REACTIVITY: Vir SENSITIVITY: Endogenous MW (kDa): 100 SOURCE: Rabbit